Last updated on August 23, 2025
Duopharma Biotech Bhd recorded a significant 21 percent year-on-year increase in net profit for the second quarter ended June 30, 2025, reaching RM20.2 million—up from RM16.7 million a year earlier. Revenue edged up 1.6 percent to RM221.78 million, supported by steady sales to government hospitals and clinics. Earnings per share likewise improved, rising to 2.10 sen from 1.73 sen.
Reflecting its stronger performance, the board declared a first interim dividend of 1.5 sen per share, amounting to RM14.43 million—an increase from last year’s one‑sen payout of RM9.62 million. The dividend is set for payment on September 24, with an ex‑dividend date of September 9.
For the first half of FY2025, Duopharma Biotech posted a net profit of RM45.84 million, marking a 43.4 percent increase from RM31.97 million over the same period in FY2024. This improvement was underpinned by a 17.8 percent revenue boost to RM484.52 million (up from RM411.29 million), driven in part by heightened public-sector demand and a one-off lift from insulin deliveries following supply normalization in the first quarter.
Despite global economic uncertainties—such as shifting U.S. tariffs and geopolitical tensions—the company does not anticipate a direct impact on its operations, though it remains cautious about potential supply chain effects. Additionally, management anticipates that the recent reduction in the overnight policy rate (OPR) will offer some insulation against rising electricity tariffs and expanded sales and service tax obligations.
